Scotland R&D plant
This article was originally published in The Tan Sheet
Executive Summary
Mentholatum announces plans to create a state-of-the-art research and development center in East Kilbride, Scotland. The firm has already invested $20 million, which will increase production capacity at the plant owned by Mentholatum's Japan-based parent company, Rohto Pharmaceutical. Mentholatum says it "aims to cement its position as a market leader in the eye, lip and personal care categories and grow its presence in the skincare market on the back of its acquisition of the high-profile Oxy brand." Mentholatum acquired the brand from GlaxoSmithKline in December 2004 (1"The Tan Sheet" Dec. 20, 2004, p. 8)...
You may also be interested in...
Mentholatum Oxy Acquisition Provides Entry Into U.S. Skin Care Market
Mentholatum will leverage technologies used in its internationally marketed skin care products to launch new innovations under the Oxy anti-acne brand, the firm said. The Rohto Pharmaceutical subsidiary acquired the line from GlaxoSmithKline Dec. 10
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.